Stock Fundamentals

Company Information

Company Name
Annexon Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US03589W1027
CIK: 0001528115
CUSIP: 03589W102
Currency: USD
Full Time Employees: 93
Phone: 650 822 5500
Fiscal Year End: December
IPO Date: Jul 24, 2020
Description:

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Address:

1400 Sierra Point Parkway, Brisbane, CA, United States, 94005

Directors & Officers

Name Title Year Born
Mr. Douglas E. Love Esq., J.D. CEO, President & Director 1968
Ms. Jennifer Lew CPA Executive VP, CFO & Corporate Secretary 1973
Dr. Ted Yednock Ph.D. Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board 1958
Dr. Dean R. Artis Ph.D. Chief Scientific Officer & Executive VP 1961
Mr. Michael Overdorf M.B.A. Executive VP & Chief Business Officer 1971
Mr. Henk-Andre Kroon M.D. Senior Vice President of Translational Medicine NA
Dr. Jamie Dananberg M.D. Executive VP & Chief Medical Officer 1958
Mr. Shikhar Agarwal M.B.A. Senior VP & Head of Commercial NA
Dr. Sunil Mehta Pharm.D. Senior VP of Medical Affairs NA
Dr. Lloyd Clark M.D. Senior Vice President of Ophthalmology Strategy & Innovation NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 10, 2026 William H Carson N/A Purchase 8.00K $6.20 $49.60K
Mar 10, 2026 William H Carson N/A Purchase 8.00K $5.67 $45.36K
Feb 18, 2026 Dean Richard Artis N/A Sale 5.29K $5.10 $26.98K
Feb 18, 2026 Jamie Dananberg N/A Sale 5.29K $5.10 $26.98K
Feb 18, 2026 Jennifer Lew N/A Sale 7.85K $5.11 $40.12K
Feb 18, 2026 Michael Overdorf N/A Sale 6.23K $5.10 $31.75K
Feb 18, 2026 Ted Yednock N/A Sale 7.86K $5.11 $40.15K
Dec 30, 2025 William H Carson N/A Purchase 4.12K $5.02 $20.66K
Dec 01, 2025 Jung Choi N/A Purchase 33.00K $4.19 $138.27K
Dec 01, 2025 William H Carson N/A Purchase 4.12K $4.47 $18.39K
Nov 21, 2025 Muneer A Satter N/A Purchase 422.61K $4.28 $1.81M
Nov 20, 2025 Muneer A Satter N/A Purchase 400.00K $4.48 $1.79M
Nov 19, 2025 Muneer A Satter N/A Purchase 500.00K $3.94 $1.97M
Nov 17, 2025 Muneer A Satter N/A Purchase 500.00K $2.99 $1.50M
Oct 30, 2025 William H Carson N/A Purchase 4.12K $3.17 $13.04K
Sep 30, 2025 William H Carson N/A Purchase 4.12K $3.05 $12.55K
Jul 30, 2025 William H Carson N/A Purchase 4.12K $2.43 $10.00K
Jul 14, 2025 Jennifer Lew N/A Sale 1.12K $2.58 $2.88K
Jul 14, 2025 Jennifer Lew N/A Sale 1.12K $2.58 $2.88K
Jul 14, 2025 Michael Overdorf N/A Sale 853.00 $2.61 $2.23K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Redmile Group, LLC 14.55M Mar 31, 2026 8.95% $5.34 44.76%
BlackRock Inc 10.94M Mar 31, 2026 6.73% $0.00 22.08%
FMR Inc 10.64M Mar 31, 2026 6.54% $0.00 4.04%
Bvf Inc 8.70M Mar 31, 2026 5.35% $1.54 -4.71%
Vanguard Group Inc 7.75M Dec 31, 2025 4.77% $0.00 32.87%
State Street Corp 6.92M Mar 31, 2026 4.26% $0.00 48.73%
Bain Capital Life Sciences Investors, LLC 5.21M Mar 31, 2026 3.21% $2.60 -0.69%
Bellevue Group AG 5.16M Mar 31, 2026 3.17% $0.68 0.00%
Mak Capital One LLC 4.72M Mar 31, 2026 2.91% $3.86 59.68%
Adage Capital Partners Gp LLC 4.30M Mar 31, 2026 2.65% $0.04 -21.82%
Bank of America Corp 4.26M Mar 31, 2026 2.62% $0.00 165.32%
Nuveen, LLC 4.25M Mar 31, 2026 2.61% $0.01 45.66%
Siren, L.L.C. 3.96M Mar 31, 2026 2.44% $0.61 0.00%
Balyasny Asset Management LLC 3.89M Mar 31, 2026 2.39% $0.03 17.81%
Ameriprise Financial Inc 3.45M Mar 31, 2026 2.12% $0.00 -20.69%
Geode Capital Management, LLC 3.38M Mar 31, 2026 2.08% $0.00 16.36%
Qube Research & Technologies 3.11M Mar 31, 2026 1.92% $0.02 30.77%
Longaeva Partners L.P. 3.10M Dec 31, 2025 1.91% $1.31 0.00%
Palo Alto Investors, LLC 2.95M Mar 31, 2026 1.81% $2.50 23.65%
Morgan Stanley - Brokerage Accounts 2.74M Mar 31, 2026 1.68% $0.00 -4.21%

Shares Statistics

Shares Outstanding: 163.84M
Shares Float: 130.11M
% Insiders: 47.20%
% Institutions: 10,271.00%
Short % Float: 15.84%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 BB Biotech AG Ord 5.16M 3.17% ▲ 0.00% Sep 30, 2025
2 Fidelity Select Biotechnology 4.73M 2.91% ▲ 0.00% Mar 31, 2026
3 Vanguard Total Stock Mkt Idx Inv 4.31M 2.65% ▲ 0.00% Apr 30, 2026
4 State Street® SPDR® S&P® Biotech ETF 4.27M 2.63% ▼ 0.70% Apr 30, 2026
5 iShares Russell 2000 ETF 3.12M 1.92% ▲ 0.85% Apr 30, 2026
6 FIAM Small Cap Core Composite 2.43M 1.50% ▼ 40.85% Dec 31, 2025
7 CREF Total Global Stock Account R3 1.82M 1.12% ▼ 6.59% Mar 31, 2026
8 Vanguard Institutional Extnd Mkt Idx Tr 1.53M 0.94% ▲ 0.52% Apr 30, 2026
9 Nuveen Quant Small Cap Equity R6 1.49M 0.92% ▲ 0.00% Mar 31, 2026
10 Columbia Small Cap Value Discv A 1.46M 0.90% ▲ 0.00% Apr 30, 2026

Valuation Metrics

Enterprise Value: $714.65M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $861.81M
EBITDA: $-202.89M
Book Value: $1.26
Earnings/Share: $-1.20
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -45.29%
ROE (TTM): -87.65%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 5.68x 0.01x 0.24x N/A -0.01x
2024-12-31 10.37x 0.01x 0.16x N/A -0.02x
2023-12-31 14.72x 0.01x 0.16x N/A -0.02x
2022-12-31 11.10x 0.01x 0.19x -39.87x -0.01x
2021-12-31 11.39x 0.01x 0.19x -61.05x -0.01x
2020-12-31 33.33x 0.00x 0.03x N/A -0.01x
2019-12-31 9.21x 0.00x 0.13x -6.98x 0.00x
2018-12-31 13.74x 0.00x 0.21x N/A 0.00x
2017-12-31 1.68x 0.00x 6.91x N/A 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ANNX.US!